Dean Wilkie

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

Li Liu, Yichen Cao, Charles Chen et al. · Cancer Research · 2006 · 1.5K citations · Full text

Chemoprevention Strategy, Immunology, Cell Death +19

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Yong S. Chang, Jalila Adnane, Pamela A. Trail et al. · Cancer Chemotherapy and Pharmacology · 2006 · 462 citations

Oncology, Medicine, Tumor Growth +10

Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma

Christine Elser, Lillian L. Siu, Eric Winquist et al. · Journal of Clinical Oncology · 2007 · 260 citations · Full text

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

Ningshu Liu, Bruce R. Rowley, Cathy Bull et al. · Molecular Cancer Therapeutics · 2013 · 251 citations

Molecular Pharmacology, Tumor Biology, Pi3k Inhibitors +15